Advice
Following a full submission
clostridium botulinum type A toxin (Dysport®) is not recommended for use within NHS Scotland for the treatment of focal spasticity, including arm symptoms associated with focal spasticity, in conjunction with physiotherapy.
Dysport® produces a localised reduction in muscle tone in patients with post-stroke upper limb spasticity and can improve patient disability at 16 weeks. It continues to be effective after repeated administrations with no new adverse events apparent. However, patient numbers in the clinical studies were small and the benefits modest. The economic case has not been demonstrated.
Download detailed advice43KB (PDF)
Medicine details
- Medicine name:
- clostridium botulinum type A toxin haemagglutinin complex (Dysport®)
- SMC ID:
- 353/07
- Indication:
- Focal spasticity
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 12 March 2007